Global Retirement Partners, LLC Seagen Inc. Transaction History

Global Retirement Partners, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 13, 2023	BUY	$191.51 - $216.16 $191 - $216	1 Added 0.44%	229 $48,000
Q2 2023 Jul 20, 2023	SELL	$187.64 - $206.25 $28,896 - $31,762	-154 Reduced 40.31%	228 $43,000
Q1 2023 May 05, 2023	SELL	$127.59 - $203.08 $1,020 - $1,624	-8 Reduced 2.05%	382 $77,000
Q4 2022 Feb 13, 2023	BUY	$117.37 - $139.17 $24,412 - $28,947	208 Added 114.29%	390 $50,000
Q4 2022 Feb 13, 2023	BUY	$117.37 - $139.17 $24,412 - $28,947	208 Added 114.29%	390 $50,000
Q3 2022 Nov 03, 2022	SELL	$135.27 - $180.11 $676 - $900	-5 Reduced 2.67%	182 $23,000
Q1 2022 Jul 14, 2022	BUY	$119.61 - $157.85 $22,367 - $29,517	187 New	187 $25,000
Q4 2021 Jan 21, 2022	SELL	$142.57 - $190.86 $11,120 - $14,887	-78 Closed	0 $0
Q3 2021 Oct 22, 2021	BUY	$142.45 - $169.82 $4,273 - $5,094	30 Added 62.5%	78 $13,000
Q2 2021 Jul 15, 2021	BUY	$135.08 - $161.1 $4,592 - $5,477	34 Added 242.86%	48 $8,000
Q1 2021 Apr 14, 2021	BUY	$137.51 - $190.8 $825 - $1,144	6 Added 75.0%	14 $2,000
Q4 2020 Jan 13, 2021	BUY	$164.63 - $211.93 $1,317 - $1,695	8 New	8 $1,000

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Global Retirement Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Global Retirement Partners, LLC with notifications on news.